Project Grant R43DK146426

The National Institute of Diabetes and Digestive and Kidney Diseases awarded Analytical Diagnostic Solutions Inc. $311,172 on August 15, 2026, to develop a point-of-care device for monitoring urinary oxalate levels in patients with oxalurias and kidney stone disease under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847).

Calcium oxalate stones account for 75–80% of all kidney stones, with hyperoxaluria—excess urinary oxalate excretion—as the primary risk factor for stone formation and recurrence. Current treatment relies on pharmacological interventions including thiazide diuretics and potassium citrate, but success depends on precise monitoring of urinary pH, creatinine, and oxalate levels. The standard 24-hour urine collection method is impractical for routine use due to long turnaround times, cumbersome sample handling, and noncompliance rates exceeding 30%, leaving management reactive rather than preventive.

The device addresses this gap by enabling real-time urine monitoring, replacing the current standard with an accessible, point-of-care solution for patients to track relevant biomarkers and share data with healthcare providers. Performance of work occurs in Mt Laurel Township, New Jersey. The award covers the period from August 15, 2026, through July 31, 2027. Analytical Diagnostic Solutions specializes in developing point-of-care diagnostic technologies for rare genetic and metabolic disorders; prior NIH-funded projects include diagnostic platforms for homocysteine, phenylketonuria, creatine phosphokinase, and adenosine deaminase 2 deficiency monitoring.